Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing

A. Srivastava, D. Skopelitou, B. Miao, S. Giagiobbe, N. Paramasivam, A. Kumar, C. Diquigiovanni, E. Bonora, OR. Bandapalli, A. Försti, K. Hemminki

. 2025 ; 192 (4) : 398-407. [pub] 20250327

Language English

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25016339

Grant support
23-05609S Czech Science Agency
National Institute for Cancer Research
LX22NPO5102 NICR
European Union-Next Generation EU
CZ.02.01.01/00/22_008/000464 SALVAGE

OBJECTIVE: Thyroid cancer (TC) is the most common endocrine malignancy, with 90%-95% of the cases representing non-medullary thyroid cancer (NMTC). Familial cases account only for a few of all cases and the underlying genetic causes are still poorly understood. METHODS: We whole-genome sequenced affected and unaffected members of an Italian NMTC family and applied our in-house developed Familial Cancer Variant Prioritization Pipeline (FCVPPv2) which prioritized 12 coding variants. We refined this selection using the VarSome American College of Medical Genetics and Genomics (ACMG) implementation, SNAP2 predictions and further in silico scores. RESULTS: We prioritized 4 possibly pathogenic variants in 4 genes including Ret proto-oncogene (RET), polypeptide N-acetylgalactosaminyltransferase 10 (GALNT10), ubinuclein-1 (UBN1), and prostaglandin I2 receptor (PTGIR). The role of RET point mutations in medullary thyroid carcinoma is well established. Similarly, somatic rearrangements of RET are known in papillary TC, a specific histotype of NMTC. In contrast to RET, no germline variants in PTGIR, GALNT10, or UBN1 have been linked to the development of TC to date. However, alterations in these genes have been shown to affect pathways related to cell proliferation, apoptosis, growth, and differentiation, as well as posttranslational modification and gene regulation. A thorough review of the available literature together with computational evidence supported the interpretation of the 4 shortlisted variants as possibly disease-causing in this family. CONCLUSIONS: Our results implicate the first germline variant in RET in a family with NMTC as well as the first germline variants in PTGIR, GALNT10, and UBN1 in TC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016339
003      
CZ-PrNML
005      
20250731092839.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ejendo/lvaf045 $2 doi
035    __
$a (PubMed)40177881
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Srivastava, Aayushi $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Heidelberg University, Medical Faculty, Heidelberg 69120, Germany
245    10
$a Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing / $c A. Srivastava, D. Skopelitou, B. Miao, S. Giagiobbe, N. Paramasivam, A. Kumar, C. Diquigiovanni, E. Bonora, OR. Bandapalli, A. Försti, K. Hemminki
520    9_
$a OBJECTIVE: Thyroid cancer (TC) is the most common endocrine malignancy, with 90%-95% of the cases representing non-medullary thyroid cancer (NMTC). Familial cases account only for a few of all cases and the underlying genetic causes are still poorly understood. METHODS: We whole-genome sequenced affected and unaffected members of an Italian NMTC family and applied our in-house developed Familial Cancer Variant Prioritization Pipeline (FCVPPv2) which prioritized 12 coding variants. We refined this selection using the VarSome American College of Medical Genetics and Genomics (ACMG) implementation, SNAP2 predictions and further in silico scores. RESULTS: We prioritized 4 possibly pathogenic variants in 4 genes including Ret proto-oncogene (RET), polypeptide N-acetylgalactosaminyltransferase 10 (GALNT10), ubinuclein-1 (UBN1), and prostaglandin I2 receptor (PTGIR). The role of RET point mutations in medullary thyroid carcinoma is well established. Similarly, somatic rearrangements of RET are known in papillary TC, a specific histotype of NMTC. In contrast to RET, no germline variants in PTGIR, GALNT10, or UBN1 have been linked to the development of TC to date. However, alterations in these genes have been shown to affect pathways related to cell proliferation, apoptosis, growth, and differentiation, as well as posttranslational modification and gene regulation. A thorough review of the available literature together with computational evidence supported the interpretation of the 4 shortlisted variants as possibly disease-causing in this family. CONCLUSIONS: Our results implicate the first germline variant in RET in a family with NMTC as well as the first germline variants in PTGIR, GALNT10, and UBN1 in TC.
650    _2
$a lidé $7 D006801
650    12
$a nádory štítné žlázy $x genetika $7 D013964
650    12
$a genetická predispozice k nemoci $x genetika $7 D020022
650    _2
$a protoonkogen Mas $7 D000090063
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a N-acetylgalaktosaminyltransferasy $x genetika $7 D017350
650    _2
$a protoonkogenní proteiny c-ret $x genetika $7 D051096
650    _2
$a rodokmen $7 D010375
650    12
$a sekvenování celého genomu $x metody $7 D000073336
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a polypeptid-N-acetylgalaktosaminyltransferasa $7 D000097763
650    12
$a neuroendokrinní karcinom $x genetika $7 D018278
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skopelitou, Diamanto $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Heidelberg University, Medical Faculty, Heidelberg 69120, Germany
700    1_
$a Miao, Beiping $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
700    1_
$a Giagiobbe, Sara $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Department of Medicine I and Clinical Chemistry, University Hospital of Heidelberg, Heidelberg 69120, Germany
700    1_
$a Paramasivam, Nagarajan $u Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT), Heidelberg 69120, Germany
700    1_
$a Kumar, Abhishek $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Clinical Cooperation Unit Molecular Hematology-Oncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
700    1_
$a Diquigiovanni, Chiara $u Unit of Medical Genetics, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40126, Italy
700    1_
$a Bonora, Elena $u Unit of Medical Genetics, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40126, Italy $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40126, Italy
700    1_
$a Bandapalli, Obul Reddy $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Heidelberg University, Medical Faculty, Heidelberg 69120, Germany
700    1_
$a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Hopp Children's Cancer Center (KiTZ), Heidelberg 69120, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg 69120, Germany $1 https://orcid.org/0000000298574728
700    1_
$a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen 32300, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
773    0_
$w MED00009634 $t European journal of endocrinology $x 1479-683X $g Roč. 192, č. 4 (2025), s. 398-407
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40177881 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092834 $b ABA008
999    __
$a ok $b bmc $g 2366895 $s 1253464
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 192 $c 4 $d 398-407 $e 20250327 $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
GRA    __
$a 23-05609S $p Czech Science Agency
GRA    __
$p National Institute for Cancer Research
GRA    __
$a LX22NPO5102 $p NICR
GRA    __
$p European Union-Next Generation EU
GRA    __
$a CZ.02.01.01/00/22_008/000464 $p SALVAGE
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options